Interview mit:
Interview von:
Produziert von:
11. Sep. 2017
Die Qual der Wahl – Combi-AD vs. CheckMate 238
Dr. Rosalia Rutter interviewt Prof. Dr. Olivier Michielin auf der ESMO 2017 zum Thema Combi-AD vs. CheckMate 238.
Referenzen:
Hauschild A et al., abstract LBA6_PR: COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K-Mutant Melanoma
Weber J et al., LBA8_PR: Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238)